AbbVie (NYSE:ABBV) reported financial results for the first quarter ended March 31, 2026, demonstrating the successful evolution of its portfolio following the loss of exclusivity for Humira.
The North Chicago-based pharmaceutical giant posted net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally), driven by exceptional performance in its immunology and neuroscience divisions.
The company reported GAAP diluted earnings per share (EPS) of $0.39.
On an adjusted basis, diluted EPS reached $2.65, which includes a $0.41 per-share headwind from acquired in-process research and development (IPR&D) and milestone expenses.
Reflecting the strong underlying momentum of its core business, AbbVie raised its full-year 2026 adjusted EPS guidance to a range of $14.08 to $14.28.
AbbVie's next-generation immunology assets continue to outperform expectations.
Skyrizi posted global net revenues of $4.483 billion, while Rinvoq reached $2.119 billion.
Together, these therapies have become the primary engines of the company’s growth, more than compensating for the continued decline of Humira, which saw global revenues fall to $688 million due to biosimilar competition.
The neuroscience portfolio emerged as another significant growth pillar, generating $2.875 billion in revenue.
The oncology segment contributed $1.631 billion, supported by the recent FDA approval of Venclexta in combination with acalabrutinib as a frontline treatment for chronic lymphocytic leukemia (CLL).
Additionally, the aesthetics segment, anchored by Botox Cosmetic, reported $1.186 billion in revenue.
Meanwhile, the quarter was marked by aggressive investment in manufacturing and research.
AbbVie announced a combined $1.78 billion in multi-site manufacturing investments to bolster its global supply chain.
While the company faced a regulatory setback with an FDA Complete Response Letter (CRL) regarding the manufacturing of trenibotE, it balanced this with new regulatory submissions for Skyrizi in Crohn’s disease and Rinvoq in alopecia areata.